Company intelligence / Profile preview
Zhejiang Hisun Pharmaceutical Co., Ltd.
Taizhou, Zhejiang, Chinahisunpharm.com ↗
- Ownership
- Private
- Employees
- ~8062
- Development stage
- Preclinical
01
Overview
The company has over 130 API products sold to more than 60 countries. It has approximately 110+ clinical trials, 100+ marketed drugs, and 30+ pipeline drugs.
- Therapeutic areas
- GastroenterologyPsychiatryCardiovascularMetabolic DisordersRheumatologyEndocrinologyImmunologyHematologyOncologyInfectious Diseases
- Modalities
- Small moleculesbiologicsrecombinant proteinsmonoclonal antibodies (mAb)antibody-drug conjugates (ADC)biosimilarsvaccines
- Industry
- Pharma
02
Drug pipeline
22 assets21 more assets in the full pipeline.
Request access →03
Partnerships
PfizerNanjing Normal University
Beyond the preview
Go deeper on Zhejiang Hisun Pharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhejiang Hisun Pharmaceutical Co., Ltd..